Both Pfizer and Moderna have received emergency use authorization (EUA) for a second booster dose of their COVID-19 vaccines in certain populations. For both products, the second booster dose is given at least four months following administration of a first booster dose of any authorized or approved COVID-19 vaccine.

• Pfizer’s Comirnaty® (COVID-19 vaccine, mRNA), developed in collaboration with BioNTech, is now authorized as a second booster dose in adults at least 50 years of age, as well as individuals who are at least 12 years old and have certain kinds of immunocompromise.
• Moderna’s Spikevax® (COVID-19 vaccine, mRNA) is authorized as a second booster dose for adults who are at least 50 years old, as well as for adults at least 18 years of age who have certain kinds of immunocompromise.